Pharma stock engaged in dealing pharmaceutical ingredients, formulations, surgical products, and many more jumped upto 10 percent in the day’s trade after Black Rock Financials Services Pvt Limited bought shares of the company.
Price Action
With a market capitalization of Rs. 222 Crores, the shares of Vaishali Pharma Limited opened at Rs. 200.50 and made an intraday high of Rs. 211.25 per equity share by gaining upto 10 percent from its previous close of Rs. 192.85.
What Happened
As per the Bulk/Block deal data available on NSE, Black Rock Financial Services Pvt Limited has purchased 92,612 equity shares of Vaishali Pharma Limited at an average price of Rs. 194.56 per equity, against the sale of the same quantity of shares by Fortune Gilts Pvt Ltd at an average price of Rs. 194.48.
The above-mentioned Black Rock Financial Services Private Limited is an unlisted company registered in Gujarat, it is a financial and insurance service company, engaged in financial advisory, brokerage, and consultancy services. It is not anywhere related to Foreign Institutional Investor BlackRock.
About the Company
Vaishali Pharma Limited is a pharmaceutical company engaged in dealing in pharmaceutical ingredient, pharmaceutical formulations, surgical products, herbal and nutraceutical products, veterinary supplements operating in domestic and global markets.
Its product categories include active pharmaceutical ingredients (APIs), formulation brands, formulations, herbal, nutraceuticals, oncology, surgical and veterinary, among others. It offers APIs, including antibiotics, anti-ulcers, cardiac, anti-diabetic, anti-platelet agents, and many others.
Financials and Ratios
Its Revenue from operations grew by 23.86 percent YoY from Rs. 69.66 Crores in FY23 to Rs. 86.28 Crores in FY24, accompanied by profits of Rs. 6.60 Crores to Rs. 72 Lakhs.
In terms of Return ratios, it has reported a return on equity (ROE) of 1.73 percent and a return on capital employed (ROCE) of 4.77 percent. It has reported a debt-to-equity ratio of 0.31.
Written by: Bharath K.S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
